Possible effects of coronavurus infection (COVID-19) on the cardiovascular system

Larina VN, Golovko MG, Larin VG
About authors

Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Vera N. Larina
Ostrovityanova, 1, Moscow, 117997; ur.liam@vaniral

About paper

Acknowledgements: the authors thank Gennady V. Poryadin, Professor at the Department of Pathophysiology and Clinical Pathophysiology (the Faculty of General Medicine, Pirogov Russian National Research Medical University), DMSc and the correspondent member of RAS, for his invaluable critical comments on this paper.

Author contribution: Larina VN conceived and planned the study, analyzed the literature, interpreted the literature data, and revised the manuscript; Golovko MG and Larin VG planned the study, analyzed the literature, interpreted the literature data, and wrote the draft of the manuscript.

Received: 2020-04-03 Accepted: 2020-04-17 Published online: 2020-04-18

Acute viral respiratory infections can increase the risk of progression of a pre-existing condition, including a cardiovascular pathology. Life-threatening complications of Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitate research into the cardiovascular effects of COVID-19 crucial for developing adequate treatment strategy for infected patients, especially those of advanced age. This article reviews the literature on the clinical and functional characteristics of patients with COVID-19, including those with poor outcomes. The article looks at the pathophysiological processes occurring in the cardiovascular system in the setting of SARS-CoV-2 infection, risk factors and death predictors. It also discusses continuation of therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with COVID-19.

Keywords: infection, coronavirus, cardiovascular diseases, severe acute respiratory syndrome, COVID-19, angiotensin-converting enzyme, SARS-CoV-2